\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={A Prospective for the Potential Effect of Local Anesthetics on Stem-Like Cells in Colon Cancer},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2020 2020-01-15 (revised: 38 Year 2020 15 January 2020)}
\def\TheID{\makeatother }
\def\TheDate{2020 2020-01-15}
\title{A Prospective for the Potential Effect of Local Anesthetics on Stem-Like Cells in Colon Cancer}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Hengrui  Liu}

\renewcommand\Authands{ and }

\date{\small \em Received: 6 December 2019 Accepted: 31 December 2019 Published: 15 January 2020}

\maketitle


\begin{abstract}
        


Colorectal cancer is the third most prevalent cancer and the second most frequent cause of cancer-related death in the world. Surgical resection of the primary tumor is the central aspect of the current multiple modes of treatment and has been associated with better prognosis. The process of surgery, including anesthetic regimens, has increasingly been recognized to affect colon cancer recurrence and metastasis. Both retrospective clinical studies and laboratory studies have reported that colon cancer cells are inhibited by some local anesthetics. However, the application of local anesthetics in colon cancer treatment is limited by our understanding of the mechanisms underlying their effects on cancer biology.

\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{A Prospective for the Potential Effect of Local Anesthetics on Stem-Like Cells in Colon Cancer}]{A Prospective for the Potential Effect of Local Anesthetics on Stem-Like Cells in Colon Cancer} 
\section[{Hengrui Liu}]{Hengrui Liu}\par
Abstract-Colorectal cancer is the third most prevalent cancer and the second most frequent cause of cancer-related death in the world. Surgical resection of the primary tumor is the central aspect of the current multiple modes of treatment and has been associated with better prognosis. The process of surgery, including anesthetic regimens, has increasingly been recognized to affect colon cancer recurrence and metastasis. Both retrospective clinical studies and laboratory studies have reported that colon cancer cells are inhibited by some local anesthetics. However, the application of local anesthetics in colon cancer treatment is limited by our understanding of the mechanisms underlying their effects on cancer biology. Local anesthetics have been proved to preferentially inhibit cancer stem cells which imply that local anesthetics target colon cancer stem cell to suppress cancer progressing. Here this paper will review and propose several potential studies, including using colon cancer cell lines and animal models to test the effect of local anesthetics on population, viability, and migration of colon cancer stem-like cell, and screen and search for potential molecular targets underlying these effects. 
\section[{I.}]{I.} 
\section[{Background}]{Background}\par
olorectal cancer is the third most prevalent cancer and the second most frequent cause of cancer-related death in the world \hyperref[b11]{12} .Surgical resection of the primary tumor is the central aspect of the current multiple modes of treatment and has been associated with better prognosis. However, metastasis is the dominant cause of death in patients with colon cancer. \hyperref[b2]{3} On top of cell migration, chemokines have been implicated in additional aspects of malignant transformation, such as proliferation, survival, and angiogenesis. \hyperref[b3]{4} The process of surgery, including anesthetic regimens, has increasingly been recognized to affect colon cancer recurrence and metastasis. \hyperref[b4]{5} Retrospective clinical studies have suggested that the use of regional anesthesia leads to improved patient outcomes. \hyperref[b5]{6,}\hyperref[b6]{7} Laboratory studies have reported that colon cancer cells are inhibited by some local anesthetics. \hyperref[b7]{8} However, the application of local anesthetics in colon cancer treatment is limited by our understanding of the mechanisms underlying their effects on cancer biology.\par
Emerging evidence has indicated a subpopulation of stem-like cells within tumors, known as CSCs, which contribute to cancer treatment failure and cancer relapse. \hyperref[b8]{9,}\hyperref[b9]{10} The cancer stem cell hypothesis is rising to be an attractive cellular mechanism that proposes a hierarchical organization within the colon tumor bulk and justifies the functional heterogeneity of solid tumors responsible for the aggressive nature of the malignancy and therapeutic refractoriness. \hyperref[b10]{11,}\hyperref[b11]{12} Amide-linked local anesthetics, lidocaine, ropivacaine, and bupivacaine, have been proved to preferentially inhibit colony formation and self-renewal of cancer stem cells. \hyperref[b12]{13} A recent study also showed that local anesthetics inhibit colon cancer not through inducing apoptosis or damaging the cell (cytotoxicity) but through arresting cell proliferation cycle. \hyperref[b13]{14} These conclusions imply that local anesthetics target colon cancer stem-like cell to suppress cancer progressing. We aim to determine the effect of local anesthetics on population, viability, and migration of colon cancer stem-like cell, and screen and search for potential molecular targets underlying these effects. The information about their potency and efficacy against colon cancer stem-like cells and the potential targets would help explain the mechanism of effect of regional anesthesia on colon cancer. 
\section[{II.}]{II.} 
\section[{Hypothesis and Potential Research in this Field}]{Hypothesis and Potential Research in this Field}\par
Here, based on previous knowledge and studies, this review proposed a hypothesis that local anesthetics target colon cancer stem cell to suppress cancer progressing. There are several aspects that can be explored: a) to explore the effects of local anesthetics on colon cancer stem-like cells. b) to explore the effects of local anesthetics on colon cancer stem-like cell in a murine cancer model. c) to explore the effects of local anesthetics on the stem-like cell population in clinical colon cancer tissue. d) to explore the potential stemness-correlate molecular mechanism underlying the effect. 
\section[{III. Potential Available Methods and Strategies}]{III. Potential Available Methods and Strategies}\par
This review proposed several potential available Methods and strategies. exposed to FITC-conjugated anti-CD44, anti-ALDH, and anti-LGR5 antibody, and further labeled with dextrancoated magnetic nan oparticles using bispecific Tetrameric Antibody Complexes (TAC). These cells will be subjected to immuno-magnetic cell separation and CD44 + , ALDH + , and LGR5 + cells can be identified as cancer stem cells.\par
Sphere culture \hyperref[b15]{16,}\hyperref[b16]{17} can also be used as another method to extract cancer stem-like cells. Cells can be cultured in ultralow attachment plates and the sphere passage cells can be identified as cancer stem cells. 
\section[{b) The effects of local anesthetics on colon cancer stem-like cell}]{b) The effects of local anesthetics on colon cancer stem-like cell}\par
The colon cancer cell lines and cancer stem-like cell line (sorted cancer cell line derived cells) can be used to test the effects of local amide-linked local anesthetics (lidocaine, ropivacaine, and bupivacaine). Local anesthetics have a wide range of uses in clinical practice and their plasma concentrations can vary widely and the peak plasma concentrations ranging between 1 and 3 µM. \hyperref[b17]{18,} {\ref 19} Clinically relevant concentrations can be used to treat the cell. 1, 2, 4, 12, 24, 48, and 72 hcan be set as treatment time.\par
Cell viability, migration, invasion, and adhesion of cell lines can be determined using MTT, Cell Cytotoxicity Assay Kit, apoptosis ELISA Kit, Flow Cytometry, wound healing, trans well, matrices assay, colony-for mingas say, tryps in detaching assay, etc. Self-renewal ability of cell linescan be determined using serial replating assays 20 . The population of cancer stemlike cells in HCT116 and HT29can be determined by cancer stem cell markers stain using the Immunohis to chemistry and Flow Cytometry method. 
\section[{c) The effects of local anesthetics on colon cancer stem-like cell in a murine colon cancer model.}]{c) The effects of local anesthetics on colon cancer stem-like cell in a murine colon cancer model.}\par
Immuno deficient NSG mouse model 21 with implantation of green fluorescent protein-labeled colon cancer cells (HT29) and cancer stem-like cells (HT29sorted by the method described previously) can be used. In the long-term treatment group, the primary tumor can be treated with clinically relevant concentration local perfusion of local anesthetics per day, while in the short-term treatment group, the animals can only be treated during the surgery.\par
Tumor development can be monitored through longitudinal magnetic resonance imaging-based morpho metric analysis and survival. Established serum markers of tumor spread can be measured serially and circulating tumor cells can be detected via fluorescence measurements. The primary tumor can be excised and collected after four weeks and the primary recurrent tumor and metastatic tissue (lung, brain, bone, etc.) can be collected. The population of cancer stem-like cell and in tumor and metastatic tissue can be determined by markers stain using Immuno his to chemistry method. 
\section[{d) The effects of local anesthetics on the stem-like cell population in clinical colon cancer tissue}]{d) The effects of local anesthetics on the stem-like cell population in clinical colon cancer tissue}\par
To determine whether local anesthetics can decrease colon cancer stem-like cell population in cancer tissue from patients, the colon cancer tissues with complete clinical pathological data can be collected from patients with and without lidocaine treatment. The Paraffin-embedded tissue microarray was constructed and the cancer stem-like cell population in cancer tissue can be determined by cancer stem cell markers \hyperref[b18]{22,}\hyperref[b19]{23,} {\ref 24} (CD44 + , CD24 ?/low , ALDH + and LGR5 + ) stain using the Immunohis to chemistry method. 
\section[{e) The effect of local anesthetics on stemness-correlate molecular features}]{e) The effect of local anesthetics on stemness-correlate molecular features}\par
The colon cancer cell lines and cancer stem-like cell line can be treated with local anesthetics. Total protein and total RNA of cells can be extracted, and proteomic analysis and gene array method can be used to screen altered protein and gene expression. QPCR, Immun of luorescence stain, Western blot, and Immunohis to chemistry methods can be used to confirm the results. Gene-knock-out method can be used to test the potential targets of local anesthetics involved in stemness-correlate signal.\par
IV. 
\section[{Conclusion}]{Conclusion}\par
This study hopes to emerge with a detailed clarification of the effect of local anesthetics on population, viability, and migration of colon cancer stem-like cell and specific molecular targets underlying these effects, and in turn, deepen our understanding of local anesthetics in colon cancer treatments. Here, this review proposed that a) Colon cancer stem-like cells will be identified and sorted out of colon cancer cell lines. b) Local anesthetics can suppress viability, migration, invasion, and adhesion more in colon cancer stem-like cellline than in colon cancer cell lines. The population of colon cancer stem-like cell in colon cancer cell lines will decrease after treating with local anesthetics. c) The population of colon cancer stem-like cell in tumor and metastatic tissue will decrease and cancer progression will be suppressed in local anesthetics treatment groups. d) The tumor tissue from patients with local anesthetics treatment has less cancer stem-like cells. e) Several targets of Local anesthetics will be identified. Advantageous molecular targets of stemness will be suppressed and disadvantageous targets of stemness will be promoted in colon cancer cells. Knocking out/down these targets can block the effects of the local anesthetics.\par
mammary stem cells and a predictor of poor clinical outcome. Cell stem cell, 1(5), pp.555-567. 24. Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T. and Sato, T., 2017. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature, 545(7653), p.187.		 		\backmatter   			 
\subsection[{Acknowledgment}]{Acknowledgment}\par
The author thanks the support of Zongxiong Liu, Weifen Chen, and Yaqi Yang. 			  			 			 			  				\begin{bibitemlist}{1}
\bibitem[Yasumura et al. ()]{b17}\label{b17} 	 		\textit{},  		 			R Yasumura 		,  		 			Y Kobayashi 		,  		 			R Ochiai 		.  		2016.  	 
\bibitem[Ginestier et al. ()]{b19}\label{b19} 	 		\textit{ALDH1 is a marker of normal and malignant human},  		 			C Ginestier 		,  		 			M H Hur 		,  		 			E Charafe-Jauffret 		,  		 			F Monville 		,  		 			J Dutcher 		,  		 			M Brown 		,  		 			J Jacquemier 		,  		 			P Viens 		,  		 			C G Kleer 		,  		 			S Liu 		,  		 			A Schott 		.  		2007.  	 
\bibitem[Ni et al. ()]{b12}\label{b12} 	 		‘Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/?-catenin’.  		 			J Ni 		,  		 			T Xie 		,  		 			M Xiao 		,  		 			W Xiang 		,  		 			L Wang 		.  	 	 		\textit{Biochemical and Biophysical Research Communications}  		2018.  	 
\bibitem[Royds et al. ()]{b5}\label{b5} 	 		‘An update on existing ongoing prospective trials evaluating the effect of anesthetic and analgesic techniques during primary Cancer surgery on Cancer recurrence or metastasis’.  		 			J Royds 		,  		 			A H Khan 		,  		 			D J Buggy 		.  	 	 		\textit{International anesthesiology clinics}  		2016. 54  (4)  p. .  	 
\bibitem[Both Bupivacaine and Levobupivacaine inhibit colon cancer cell growth but not melanoma cells in vitro]{b7}\label{b7} 	 		\textit{Both Bupivacaine and Levobupivacaine inhibit colon cancer cell growth but not melanoma cells in vitro},  		 	 
\bibitem[Ferlay et al. ()]{b0}\label{b0} 	 		‘Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012’.  		 			J Ferlay 		,  		 			I Soerjomataram 		,  		 			R Dikshit 		,  		 			S Eser 		,  		 			C Mathers 		,  		 			M Rebelo 		,  		 			D M Parkin 		,  		 			D Forman 		,  		 			F Bray 		.  	 	 		\textit{International journal of cancer}  		2015. 136 p. .  	 
\bibitem[Yu et al. ()]{b8}\label{b8} 	 		‘Cancer stem cells’.  		 			Z Yu 		,  		 			T G Pestell 		,  		 			M P Lisanti 		,  		 			R G Pestell 		.  	 	 		\textit{The International Journal of Biochemistry \& Cell Biology}  		2012. 44 p. .  	 
\bibitem[Singh et al. ()]{b3}\label{b3} 	 		‘Chemokines: key players in cancer progression and metastasis’.  		 			R Singh 		,  		 			J W LilladrJr 		,  		 			S Singh 		.  	 	 		\textit{Frontiers in bioscience}  		2011. 3 p. 1569.  	 	 (Scholar edition) 
\bibitem[Ricci-Vitiani et al. ()]{b11}\label{b11} 	 		‘Colon cancer stem cells’.  		 			L Ricci-Vitiani 		,  		 			E Fabrizi 		,  		 			E Palio 		,  		 			R De Maria 		.  	 	 		\textit{J Mol Med}  		2009. 87 p. .  	 
\bibitem[Vatandoust et al. ()]{b2}\label{b2} 	 		‘Colorectal cancer: Metastases to a single organ’.  		 			S Vatandoust 		,  		 			T J Price 		,  		 			C S Karapetis 		.  	 	 		\textit{World journal of gastroenterology}  		2015. 21  (41)  p. 11767.  	 
\bibitem[Bundscherer et al. ()]{b13}\label{b13} 	 		‘Effects of lidocaine on HT-29 and SW480 colon cancer cells in vitro’.  		 			A C Bundscherer 		,  		 			M Malsy 		,  		 			D I Bitzinger 		,  		 			C H Wiese 		,  		 			M A Gruber 		,  		 			B M Graf 		.  	 	 		\textit{Anticancer research}  		2017. 37  (4)  p. .  	 
\bibitem[O'leary et al. ()]{b4}\label{b4} 	 		‘Effects of surgery on the cancer stem cell niche’.  		 			D P O'leary 		,  		 			E O'leary 		,  		 			N Foley 		,  		 			T G Cotter 		,  		 			J H Wang 		,  		 			H P Redmond 		.  	 	 		\textit{European Journal of Surgical Oncology (EJSO)}  		2016. 42  (3)  p. .  	 
\bibitem[Call et al. ()]{b6}\label{b6} 	 		‘Factors associated with improved survival after resection of pancreatic Adenocarcinoma A multivariable model’.  		 			T R Call 		,  		 			N L Pace 		,  		 			D B Thorup 		,  		 			D Maxfield 		,  		 			B Chortkoff 		,  		 			J Christensen 		,  		 			S J Mulvihill 		.  	 	 		\textit{Anesthesiology: The Journal of the American Society of Anesthesiologists}  		2015. 122  (2)  p. .  	 
\bibitem[Boman and Huang ()]{b10}\label{b10} 	 		‘Human colon cancer stem cells: a new paradigm in gastrointestinal oncology’.  		 			B M Boman 		,  		 			E Huang 		.  	 	 		\textit{Journal of Clinical Oncology}  		2008. 26  (17)  p. .  	 
\bibitem[Al-Hajj et al. ()]{b18}\label{b18} 	 		‘Prospective identification of tumorigenic breast cancer cells’.  		 			M Al-Hajj 		,  		 			M S Wicha 		,  		 			A Benito-Hernandez 		,  		 			S J Morrison 		,  		 			M F Clarke 		.  	 	 		\textit{Proceedings of the National Academy of Sciences}  		2003. 100  (7)  p. .  	 
\bibitem[Usher-Smith et al. ()]{b1}\label{b1} 	 		‘Risk Prediction Models for Colorectal Cancer: a Systematic Review’.  		 			J Usher-Smith 		,  		 			F Walter 		,  		 			J Emery 		,  		 			A Win 		,  		 			S Griffin 		.  		 \xref{http://dx.doi.org/10.1158/1940-6207;CAPR-15-0274}{10.1158/1940-6207;CAPR-15-0274}.  	 	 		\textit{Cancer Prev. Res}  		2016. 9 p. .  	 
\bibitem[Patel et al. ()]{b14}\label{b14} 	 		‘Silibinin, A Natural Blend In Polytherapy Formulation For Targeting Cd44v6 Expressing Colon Cancer Stem Cells’.  		 			S Patel 		,  		 			B Waghela 		,  		 			K Shah 		,  		 			F Vaidya 		,  		 			S Mirza 		,  		 			S Patel 		,  		 			C Pathak 		,  		 			R Rawal 		.  	 	 		\textit{Scientific reports}  		2018. 8  (1)  p. 16985.  	 
\bibitem[Cao et al. ()]{b15}\label{b15} 	 		‘Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines’.  		 			L Cao 		,  		 			Y Zhou 		,  		 			B Zhai 		,  		 			J Liao 		,  		 			W Xu 		,  		 			R Zhang 		,  		 			J Li 		,  		 			Y Zhang 		,  		 			L Chen 		,  		 			H Qian 		,  		 			M Wu 		.  	 	 		\textit{BMC gastroenterology}  		2011. 11  (1)  p. 71.  	 
\bibitem[Weiswald et al. ()]{b16}\label{b16} 	 		‘Spherical cancer models in tumor biology’.  		 			L B Weiswald 		,  		 			D Bellet 		,  		 			V Dangles-Marie 		.  	 	 		\textit{Neoplasia}  		2015. 17  (1)  p. .  	 
\bibitem[Dragu et al. ()]{b9}\label{b9} 	 		‘Therapies targeting cancer stem cells: current trends and future challenges’.  		 			D L Dragu 		,  		 			L G Necula 		,  		 			C Bleotu 		,  		 			C C Diaconu 		,  		 			M Chivu-Economescu 		.  	 	 		\textit{World journal of stem cells}  		2015. 7  (9)  p. 1185.  	 
\end{bibitemlist}
 			 		 	 
\end{document}
